311 related articles for article (PubMed ID: 32129111)
1. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.
Facchinetti F; Appetecchia M; Aragona C; Bevilacqua A; Bezerra Espinola MS; Bizzarri M; D'Anna R; Dewailly D; Diamanti-Kandarakis E; Hernández Marín I; Kamenov ZA; Kandaraki E; Laganà AS; Monastra G; Montanino Oliva M; Nestler JE; Orio F; Ozay AC; Papalou O; Pkhaladze L; Porcaro G; Prapas N; Soulage CO; Stringaro A; Wdowiak A; Unfer V
Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):255-274. PubMed ID: 32129111
[No Abstract] [Full Text] [Related]
2. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
Facchinetti F; Unfer V; Dewailly D; Kamenov ZA; Diamanti-Kandarakis E; Laganà AS; Nestler JE; Soulage CO;
Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
[TBL] [Abstract][Full Text] [Related]
3. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future.
Laganà AS; Myers SH; Forte G; Naem A; Krentel H; Allahqoli L; Alkatout I; Unfer V
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):61-72. PubMed ID: 38226638
[TBL] [Abstract][Full Text] [Related]
4. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
5. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
[TBL] [Abstract][Full Text] [Related]
6. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
7. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
Wojciechowska A; Osowski A; Jóźwik M; Górecki R; Rynkiewicz A; Wojtkiewicz J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752081
[TBL] [Abstract][Full Text] [Related]
8. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
Monastra G; Unfer V; Harrath AH; Bizzarri M
Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
[TBL] [Abstract][Full Text] [Related]
9. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
Facchinetti F; Bizzarri M; Benvenga S; D'Anna R; Lanzone A; Soulage C; Di Renzo GC; Hod M; Cavalli P; Chiu TT; Kamenov ZA; Bevilacqua A; Carlomagno G; Gerli S; Oliva MM; Devroey P
Eur J Obstet Gynecol Reprod Biol; 2015 Dec; 195():72-76. PubMed ID: 26479434
[TBL] [Abstract][Full Text] [Related]
10. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.
Sortino MA; Salomone S; Carruba MO; Drago F
Front Pharmacol; 2017; 8():341. PubMed ID: 28642705
[TBL] [Abstract][Full Text] [Related]
11. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
[TBL] [Abstract][Full Text] [Related]
12. Inositols in the ovaries: activities and potential therapeutic applications.
Laganà AS; Forte G; Bizzarri M; Kamenov ZA; Bianco B; Kaya C; Gitas G; Alkatout I; Terzic M; Unfer V
Expert Opin Drug Metab Toxicol; 2022 Feb; 18(2):123-133. PubMed ID: 35472446
[TBL] [Abstract][Full Text] [Related]
13. Inositols in PCOS.
Kamenov Z; Gateva A
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260918
[TBL] [Abstract][Full Text] [Related]
14. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Nordio M; Basciani S; Camajani E
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
[TBL] [Abstract][Full Text] [Related]
15. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
16. Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART).
Facchinetti F; Espinola MSB; Dewailly D; Ozay AC; Prapas N; Vazquez-Levin M; Wdowiak A; Unfer V;
Trends Endocrinol Metab; 2020 Aug; 31(8):570-579. PubMed ID: 32418772
[TBL] [Abstract][Full Text] [Related]
17. Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Paul C; Laganà AS; Maniglio P; Triolo O; Brady DM
Gynecol Endocrinol; 2016 Jun; 32(6):431-8. PubMed ID: 26927948
[TBL] [Abstract][Full Text] [Related]
18. Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
Galletta M; Grasso S; Vaiarelli A; Roseff SJ
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1212-4. PubMed ID: 22165685
[TBL] [Abstract][Full Text] [Related]
19. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
Colazingari S; Treglia M; Najjar R; Bevilacqua A
Arch Gynecol Obstet; 2013 Dec; 288(6):1405-11. PubMed ID: 23708322
[TBL] [Abstract][Full Text] [Related]
20. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome.
Lete I; Martínez A; Lasaga I; Centurión E; Vesga A
Gynecol Endocrinol; 2024 Dec; 40(1):2301554. PubMed ID: 38239032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]